Document:

EXHIBIT 10.1

                   Paul Intlekofer Elected CEO of Nutrition 21

      PURCHASE, N.Y., April 26, 2006 - Nutrition 21, Inc., (NASDAQ: NXXI) today
announced that its Board of Directors has elected Paul Intlekofer as president
and chief executive officer. Mr. Intlekofer has been serving as chief financial
officer and senior vice president of corporate development since January 2003
and most recently was elected chief operating officer in November 2005.

      "Paul Intlekofer's proven leadership and strategic vision have been the
driving force behind the company's current transition toward becoming a supplier
of branded finished products addressing therapeutic markets," said John
Gutfreund, Chairman of the Board. "Mr. Intlekofer possesses a unique mix of
strategic vision, passion and operational discipline that has served and will
continue to serve Nutrition 21 well. The Board is confident that Mr. Intlekofer
is the right person to realize the potential of Nutrition 21."

      "I am honored to be selected CEO," said Intlekofer. "I know first hand
that we have great products that address significant and growing markets. Over
the past several years we've made a considerable investment in research to
clinically validate our proprietary technologies. We recently built out an
experienced and talented sales and marketing team to capitalize on these
findings. Their contribution and pace of execution gives me great confidence in
the long-term future and growth of the company."

      Since January of 2006, the Company has secured distribution for its
Chromax(R) chromium picolinate in Wal-Mart, Rite Aid, Albertsons, Kroger and
another major drug chain. The Company expects to have full nationwide
distribution in these and over 90 percent of food, drug and mass outlets by the
end of the summer. The Company is also working with the retailers to create an
Insulin Health end-benefit destination on the shelf for chromium picolinate
similar to Bone Health for calcium.

      "With an aging baby boomer population and the rise of obesity there are
tens of millions of adults concerned with their blood sugar and cholesterol
levels and their risk for developing heart disease and type 2 diabetes. As a
natural solution for managing insulin, Chromax can become an everyday product
similar to calcium. In the U.S. alone, calcium accounts for $1 billion in retail
stand-alone sales," added Intlekofer.

<PAGE>

      Nutrition 21 also recently secured a commitment from CVS/pharmacy for
Diachrome, a non-prescription nutrient based insulin sensitizer for people with
type 2 diabetes. The Company expects to have full nationwide distribution of
Diachrome with the major drug chains by the Fall to coincide with the
publication of its recently completed study with XLHealth.

      "The key to success for Diachrome is to secure endorsement and
recommendation from pharmacists and healthcare providers. We've taken
considerable steps to substantiate Diachrome's health benefits and the early
results indicate that physicians are impressed with Diachrome's efficacy and
safety. We have developed an innovative marketing strategy that will leverage
the managed care/disease management information infrastructure to communicate
the benefits of Diachrome to the healthcare community," said Intlekofer.

CONTACT: Maryrose Lombardo, 914.701.4525

ABOUT NUTRITION 21
Nutrition 21 is a nutritional bioscience company and the maker of chromium-based
supplements with health benefits substantiated by clinical research. The Company
markets Chromax(R) chromium picolinate, http://www.chromax.com/, the
most-studied form of the essential mineral chromium which is now available
through food, drug and mass retailers nationwide. Nutrition 21 also developed
Diachrome(R), http://www.diachrome.com, a proprietary adjunct nutritional
therapy for people with type 2 diabetes. Nutrition 21 holds 36 patents for
nutrition products and uses, 27 of which are for chromium compounds and their
uses. More information is available at http://www.nutrition21.com.

SAFE HARBOR PROVISION
This press release may contain certain forward-looking statements. The words
"believe," "expect," "anticipate" and other similar expressions generally
identify forward-looking statements. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of their
dates. These forward-looking statements are based largely on the Company's
current expectations and are subject to a number of risks and uncertainties,
including without limitation: the effect of the expiration of patents;
regulatory issues; uncertainty in the outcomes of clinical trials; changes in
external market factors; changes in the Company's business or growth strategy or
an inability to execute its strategy due to changes in its industry or the
economy generally; the emergence of new or growing competitors; various other
competitive factors; and other risks and uncertainties indicated from time to
time in the Company's filings with the Securities and Exchange Commission,
including its Form 10-K for the year ended June 30, 2005 and subsequent reports
on From 10-Q. Actual results could differ materially from the results referred
to in the forward-looking statements. In light of these risks and uncertainties,
there can be no assurance that the results referred to in the forward-looking
statements contained in this press release will in fact occur. Additionally, the
Company makes no commitment to disclose any revisions to forward-looking
statements, or any facts, events or circumstances after the date hereof that may
bear upon forward-looking statements.

                                      # # #Form
      of Revised Director Indemnity Agreement

     

    [Marked
      to reflect additions to the Director Indemnity Agreement previously approved
      by
      the Shareholders Meeting]

     

    AGREEMENT,
      dated as of ___________________, between RadwareLtd., an Israeli company (the
      “Company”),
      and
      ________, a director and Office Holder of the Company (the “Indemnitee”).

     

     

    
      	WHEREAS, 	
              Indemnitee
                is a director and/or Office Holder of the Company;

            
	 	 
	WHEREAS,	
              both
                the Company and Indemnitee recognize the risk of litigation and other
                claims being asserted against Office Holders of public companies;
                

            
	 	 
	WHEREAS,
              	
              the
                Articles of Association of the Company authorize the Company to indemnify
                directors; and

            
	 	 
	WHEREAS,	
              in
                recognition of Indemnitee’s need for substantial protection against
                personal liability in order to assure Indemnitee’s continued service to
                the Company in an effective manner and Indemnitee’s reliance on the
                aforesaid Articles of Association and, in part, to provide Indemnitee
                with
                specific contractual assurance that the protection promised by the
                Articles of Association will be available to Indemnitee (regardless
                of,
                among other things, any amendment to or revocation or any change
                in the
                composition of the Company’s Board of Directors or acquisition of the
                Company), the Company wishes to provide in this Agreement for the
                indemnification of and the advancing of expenses to Indemnitee to
                the full
                extent (whether partial or complete) permitted by law and as set
                forth in
                this Agreement.

            

    

     

    NOW,
      THEREFORE,
      in
      consideration of the foregoing premises and of Indemnitee continuing to serve
      the Company directly or, at its request, with another enterprise, and intending
      to be legally bound hereby, the parties hereto agree as follows: 

     

    1.
       CERTAIN
      DEFINITIONS

     

    
      	
              1.1

            	
              Change
                in Control:
                shall be deemed to have occurred if: (i) any “person” (as such term is
                used in Section 13(d) and 14(d) of the Securities Exchange Act of
                1934, as
                amended), other than a trustee or other fiduciary holding securities
                under
                an employee benefit plan of the Company or a corporation owned directly
                or
                indirectly by the shareholders of the Company in substantially the
                same
                proportions as their ownership of shares of the Company, is or becomes
                the
                “beneficial owner” (as defined in Rule 13d-3 under said Act), directly or
                indirectly, of securities of the Company representing 20% or more
                of the
                total voting power represented by the Company’s then outstanding voting
                securities; or (ii) during any period of two consecutive years,
                individuals who at the beginning of such period constitute the Board
                of
                Directors of the Company and any new director whose election by the
                Board
                of Directors or nomination for election by the Company’s shareholders was
                approved by a majority of the directors then still in office who
                either
                were directors at the beginning of the period of whose election or
                nomination for election was previously so approved, cease for any
                reason
                to constitute a majority thereof; or (iii) the shareholders of the
                Company
                approve a merger or consolidation of the Company with any other
                corporation, other than a merger or consolidation which would result
                in
                the voting securities of the Company outstanding immediately prior
                thereto
                continuing to represent (either by remaining outstanding or by being
                converted into voting securities of the surviving entity) at least
                80% of
                the total voting power represented by the voting securities of the
                Company
                or such surviving entity outstanding immediately after such merger
                or
                consolidation, or the shareholders of the Company approve a plan
                of
                complete liquidation of the Company or an agreement for the sale
                or
                disposition by the Company of all or substantially all the Company’s
                assets.

            

      	 	 

      	1.2	
              Company:
                means
                Radware Ltd., and for the purpose of section 2 and the Events listed
                in
                Schedule A shall include subsidiaries, affiliates, local branches
                and
                representative offices or Radware Ltd.

            

      	 	 

      	1.3	
              Office
                Holder:
                as such term is defined in the Companies Law - 5759-1999.
                

            

      	 	 

      	1.4	
              Events:
                mean events which the Company’s Board of Directors determined, in light of
                the Company’s actual operations, to be foreseeable events which may expose
                the Indemnitee to liability or expense, as detailed in Schedule A
                to this
                Agreement.

            

      	 	 

      	1.5	
              Position:
                means the position of an Office Holder in the Company or any subsidiary
                of
                the Company or any entity in which Indemnitee serves as an Office
                Holder
                at the request of the Company either prior to or after the date
                hereof

            

    

     

     

    
      
         

      

      
         

        
          

        

      

      
        2

      

       

    

    
      	
              2.
                

            	
              INDEMNIFICATION
                AND ADVANCEMENT OF
                EXPENSES

            

    

     

    
      	
              2.1

            	
              The
                Company hereby undertakes to indemnify the Indemnitee to the fullest
                extent permitted by applicable law, for any liability and expense
                that may
                be imposed on him/her with respect to the
                following:

            

    

     

    
      	 	
              2.1.1

            	
              monetary
                liability imposed on the Indemnitee in favor of a third party in
                a
                judgment, including a settlement or an arbitral award confirmed by
                a
                court, for an act that the Indemnitee performed by virtue of being
                an
                Office Holder of the Company and/or holding any Position;
                and

            

      	 	 	 

      	 	2.1.2	
              reasonable
                litigation expenses, including attorney’s fees, expended by the Indemnitee
                as a result of an investigation or proceeding instituted against
                him or
                her by a competent authority, provided that such investigation or
                proceeding concluded without the filing of an indictment against
                him or
                her and either (A) concluded without the imposition of any financial
                liability in lieu of criminal proceedings or (B) concluded with the
                imposition of a financial liability in lieu of criminal proceedings
                but
                relates to a criminal offense that does not require proof of criminal
                intent; and

            

      	 	 	 

      	 	2.1.3  	
              reasonable
                costs of litigation, including attorneys’ fees, expended by the Indemnitee
                or for which the Indemnitee has been charged by a court, in an action
                brought against the Indemnitee by or on behalf of the Company or
                a third
                party, or in a criminal action in which the Indemnitee was acquitted,
                or
                in a criminal offense for which the Indemnitee was convicted and
                for which
                a proof of criminal intent is not
                required.

            

      	 	 	 

      	 	 	The
              above indemnification shall apply to any act performed or failure to
              act
              by the Indemnitee in his/her capacity as an Office Holder of the Company
              or as the holder of any Position. 

    

     

     

    
      	
              2.2

            	
              The
                Company’s indemnification undertaking pursuant
                to Section 2.1.1
                shall cover the Events described in Schedule A hereto, and the
                indemnification amount payable by the Company under Section
                2.1.1
                for each Event shall be limited to the amounts set forth in Schedule
                A.
                The Company’s
                board of directors determined that
                the amounts set forth in Schedule A are reasonable considering the
                nature
                of the event. 

            

    

     

     

    
      	
              2.3

            	
              If
                so requested by Indemnitee, the Company shall advance an amount (or
                amounts) estimated by it to cover Indemnitee’s reasonable litigation
                expenses, including attorneys’ fees, with respect to which Indemnitee is
                entitled to be indemnified under Section 2.1 above.
                

            

    

     

     

    
      	
              2.4

            	
              The
                Company’s obligation to indemnify Indemnitee and advance expenses in
                accordance with this Agreement shall be for such period as Indemnitee
                shall be subject to any possible claim or threatened, pending or
                completed
                action, suit or proceeding or any inquiry or investigation, whether
                civil,
                criminal or investigative, arising out of the Indemnitee’s service in the
                foregoing positions, whether or not Indemnitee is still an
                Office Holder of the Company
                or
                serving in any Position (the “Indemnification
                Period”).
                

            

      	 	 

      	3. 	
              GENERAL
                LIMITATIONS ON
                INDEMNIFICATION

            

    

     

    
      	
              3.1

            	
              If,
                when and to the extent that the Indemnitee would not be permitted
                to be so
                indemnified under applicable law, the Company shall be entitled to
                be
                reimbursed by Indemnitee (who hereby agrees to reimburse the Company)
                for
                all such amounts theretofore paid, unless Indemnitee has commenced
                legal
                proceedings in a court of competent jurisdiction to secure a determination
                that Indemnitee should be indemnified under applicable law, in which
                event
                Indemnitee shall not be required to so reimburse the Company until
                a final
                judicial determination is made with respect thereto as to which all
                rights
                of appeal therefrom have been exhausted or lapsed. In addition, in
                such
                event the Company shall not be obligated to indemnify or advance
                any
                additional amounts to Indemnitee, unless there has been a determination
                by
                a court or competent jurisdiction that the Indemnitee would be permitted
                to be so indemnified under this Agreement.

            

    

     

    
      	
              3.2

            	
              The
                Company undertakes that in the event of a Change in Control of the
                Company, the Company’s obligations under this Agreement shall continue to
                be in effect following such Change in Control, such as by ensuring
                that
                the party acquiring control of the Company shall independently undertake
                to continue in effect this Agreement or, if not applicable, enter
                into a
                similar agreement with Indemnitee on terms and conditions at least
                as
                favorable to Indemnitee as this Agreement, to maintain the provisions
                of
                the Articles of Association allowing indemnification, if applicable,
                and,
                in any event, to indemnify Indemnitee in the event that the Company
                shall
                not have sufficient funds or otherwise shall not be able to fulfill
                its
                obligations hereunder. 

            

      	 	 

      	4.	NO MODIFICATION.

    

     

    
      	 	
              No
                supplement, modification or amendment of this Agreement shall be
                binding
                unless executed in writing by both of the parties hereto. No waiver
                of any
                of the provisions of this Agreement shall be deemed or shall constitute
                a
                waiver of any other provisions hereof (whether or not similar) nor
                shall
                such waiver constitute a continuing waiver. Any waiver shall be in
                writing. 

            

    

     

     

    
      
         

      

      
         

        
          

        

      

      
        3

      

    

     

    
       

      
        	5. 	
                SUBROGATION.

              

        	 	 

        	 	
                In
                  the event of payment under this Agreement, the Company shall be
                  subrogated
                  to the extent of such payment to all of the rights of recovery
                  of
                  Indemnitee, who shall execute all documents required and take any
                  actions
                  which may be necessary to secure such rights, including the execution
                  of
                  such documents necessary to enable the Company to effectively bring
                  suit
                  to enforce such rights. 

              

        	 	 

        	6.	REIMBURSEMENT.

        	 	 

        	 	
                The
                  Company shall not be liable under this Agreement to make any payment
                  in
                  connection with any claim made against Indemnitee to the extent
                  Indemnitee
                  has otherwise received payment (under any insurance policy or otherwise)
                  of the amounts indemnified hereunder. Any amounts paid to Indemnitee
                  under
                  such insurance policy or otherwise after the Company has indemnified
                  the
                  Indemnitee for such liability or expense shall be repaid to the
                  Company
                  promptly upon receipt by Indemnitee. 

              

        	 	 

        	7.	EFFECTIVENESS.

        	 	 

        	 	
                Subject
                  to the receipt of all the required approvals in accordance with
                  the
                  Israeli Law, including the approvals of the audit committee, the
                  Board of
                  Directors and to the extent required, by the shareholders of the
                  Company,
                  this Agreement shall be in full force and effect as of the date
                  hereof.
                  

              

        	 	 

        	8.	
                NOTIFICATION
                  AND DEFENSE OF CLAIM.

              

        	 	 

        	
                8.1

              	
                Promptly
                  after receipt by Indemnitee of notice of the commencement of any
                  action,
                  suit or proceeding which may give rise to an indemnity claim by
                  Indemnitee
                  under this Agreement, Indemnitee will promptly notify the Company
                  in
                  writing of the commencement hereof; but the omission so to notify
                  the
                  Company will not release the Company from any liability which it
                  may have
                  under this Agreement. With respect to any such action, suit or
                  proceeding
                  of which Indemnitee notifies the Company, and without derogating
                  from
                  Clause 2.1: 

              

        	 	 

        	 	8.1.1    The Company will be
                entitled to participate therein at its own expense;
                and

        	 	 

        	 	8.1.2    Except
                as otherwise provided below, the Company (jointly with any other
                indemnifying party) will be entitled (but is not obligated) to assume
                the
                defense thereof, with counsel reasonably satisfactory to Indemnitee.
                After
                notice from the Company to Indemnitee of its election to assume the
                defense thereof, the Company will not be liable to Indemnitee under
                this
                Agreement for any legal or other expenses subsequently incurred by
                Indemnitee in connection with the defense thereof other than reasonable
                costs of investigation or as otherwise provided below. In the event
                the
                Company has assumed the defense as provided herein, Indemnitee shall
                have
                the right to engage a separate counsel in such action, suit or proceeding
                at his/her expense. The Company, however, will bear the expense or
                indemnify the Indemnitee for the fees of such separate counsel in
                the
                following events: (i) the engagement of counsel by Indemnitee has
                been
                authorized by the Company in writing and in advance; or (ii) Indemnitee
                shall have reasonably concluded that there may be a conflict of interest
                between the Company and the Indemnitee in the conduct of the defense
                of
                such action. 

      

    

     

    
      	
              8.2

            	
              The
                Company shall not be liable to indemnify the Indemnitee under this
                Agreement for any amounts paid in settlement of any action or claim
                effected without its written consent. The Company shall not settle
                any
                action or claim in any manner which would impose any penalty or limitation
                on the Indemnitee without the Indemnitee’s written consent. Neither the
                Company nor the Indemnitee will unreasonably withhold their consent
                to any
                proposed settlement. 

            

      	 	 

      	9.	NON-EXCLUSIVITY.

    

     

    
      	 	
              The
                rights of the Indemnitee hereunder shall not be deemed exclusive
                of any
                other rights he/she may have under the Company’s Articles of Association
                or applicable law or otherwise, and to the extent that during the
                Indemnification Period the rights of the then existing directors
                and
                Office Holders are more favorable to such directors or Office Holders
                than
                the rights currently provided thereunder or under this Agreement
                to
                Indemnitee, Indemnitee shall be entitled to the full benefits of
                such more
                favorable rights. 

            

      	 	 

      	10.	BINDING EFFECT.

    

     

    
      	 	
              This
                Agreement shall be binding upon and inure to the benefit of and be
                enforceable by the parties hereto and their respective successors,
                assigns, including any direct or indirect successor by purchase,
                merger,
                consolidation or otherwise to all or substantially all of the business
                and/or assets of the Company, spouses, heirs and personal and legal
                representatives. This Agreement shall continue in effect during the
                Indemnification Period, regardless of whether Indemnitee continues
                to
                serve as an Office Holder or director of the Company or of any other
                enterprise at the Company’s request.

            

    

     

    
      
         

      

      
         

        
          

        

      

      
        4

      

    

     

     

    
      	11.	SEVERABILITY.

      	 	 

      	 	
              The
                provisions of this Agreement shall be severable in the event that
                any
                provision hereof (including any provision within a single section,
                paragraph or sentence) is held by a court of competent jurisdiction
                to be
                invalid, void or otherwise unenforceable, and the remaining provisions
                shall remain enforceable to the fullest extent permitted by law.
                

            

      	 	 

      	12.	
              GOVERNING
                LAW, JURISDICTION.

            

      	 	 

      	 	
              This
                Agreement shall be governed by and construed and enforced in accordance
                with the laws of the State of Israel. The parties hereto irrevocably
                submit to the exclusive jurisdiction of the courts of Tel-Aviv in
                any
                action related to this Agreement.

            

      	 	 

      	13.	
              ENTIRE
                AGREEMENT AND TERMINATION.

            

      	 	 

      	 	
              This
                Agreement represents the entire agreement between the parties; and
                there
                are no other agreements, contracts or understandings between the
                parties
                with respect to the subject matter of this Agreement. No termination
                or
                cancellation of this Agreement shall be effective unless in writing
                and
                signed by both parties hereto. 

            

    

     

     

    RADWARE
      LTD.                       
Name:
      ________________

    By:                                                 
      Signature:
      _____________

     

    
      
         

      

      
         

        
          

        

      

      
        5

      

    

     

    Schedule
      A

     

    
      	
               

              1.

            	 	
               

              Negotiations,
                execution, delivery and performance of agreements on behalf of the
                Company, including, without derogating from the generality of the
                foregoing, claims for breach of contract, breach of warranty or false
                representations

               

            	 	
               

              $20,000,000

               

            
	
               

              2.

            	 	
               

              Without
                derogating from the above, acts and omissions in connection with
                the sale
                and/or purchase of assets, shares and/or legal entities, including
                any
                investments, mergers and acquisitions 

               

            	 	
               

              $20,000,000

               

            
	
               

              3.

            	 	
               

              Anti-competitive
                acts and acts of commercial wrongdoing

               

            	 	
               

              $20,000,000

               

            
	
               

              4.

            	 	
               

              Acts
                in regard of invasion of privacy including, without limitation, with
                respect to databases and acts in regard of slander

               

            	 	
               

              $20,000,000

               

            
	
               

              5.

               

            	 	
               

              Acts
                in regard of violation of copyrights, patents, trademarks, service
                marks,
                designs and any other intellectual property rights; Acts in connection
                with the intellectual property of the Company and/or Affiliates,
                and its
                protection, including the registration or assertion of rights to
                intellectual property and the defense of claims related to intellectual
                property

               

            	 	
               

              $20,000,000

               

            
	
               

              6.

            	 	
               

              Acts
                in regard of “Y2K” malfunctions

               

            	 	
               

              $5,000,000

               

            
	
               

              7.

            	 	
               

              Approval
                of corporate actions including the approval of the 

               

               

              acts
                of the Company’s management, their guidance and their
                supervision

               

            	 	
               

              $20,000,000

               

            
	
               

              8.

            	 	
               

              Claims
                of failure to exercise business judgment and a reasonable level of
                proficiency, expertise and care in regard of the Company’s business
                

               

            	 	
               

              $20,000,000

               

            
	
               

              9.

            	 	
               

              Violations
                of securities laws of any jurisdiction, including without limitation,
                fraudulent disclosure claims, failure to comply with SEC and/or Nasdaq
                rules and other claims relating to relationships with investors and
                the
                investment community

               

            	 	
               

              $30,000,000

               

            
	
               

              10.

            	 	
               

              Without
                derogating from the above, any claim in connection with the offering
                of
                the Company’s securities to the public and/or based on a prospectus any
                other public filings made by the Company

               

            	 	
               

              $20,000,000

               

            

    

    
      
         

      

      
         

        
          

        

      

      
         

        6

      

    

    

    
      	
               

              11.

            	 	
               

              Violations
                of laws requiring the Company to obtain regulatory and governmental
                licenses, permits and authorizations in any jurisdiction

               

            	 	
               

              $20,000,000

               

            
	
               

              12.

            	 	
               

              Claims
                in connection with publishing or providing any information, including
                any
                filings with governmental authorities, on behalf of the Company in
                the
                circumstances required under applicable laws

               

            	 	
               

              $20,000,000

               

            
	
               

              13.

            	 	
               

              Violations
                of any law or regulation governing domestic and international trade
                in any
                jurisdiction, including, without limitation, export laws.

               

            	 	
               

              $10,000,000

               

            
	
               

              14.

            	 	
               

              Claims
                in connection with employment relationships with Company’s or its
                subsidiaries’ employees, including, without limitations, claims for
                severance, unfair dismissal, harassment and discrimination

               

            	 	
               

              $10,000,000
                per case

               

            
	
               

              15.

            	 	
               

              Acts
                or omissions in connection with the management and operation of the
                Company, including, without limitation, claims in connection with
                the
                Company’s relationship with suppliers, customers, distributors, resellers,
                subcontractors, lessors and lessees

               

            	 	
               

              $10,000,000

               

            
	
               

              16.

            	 	
               

              Without
                derogating from the above, acts and omissions in connection with
                the
                management and monitoring of the Company’s funds and assets

               

            	 	
               

              $20,000,000

               

            
	
               

              17.

            	 	
               

              Actions
                taken pursuant to or in accordance with the policies and procedures
                of the
                Company, whether such policies and procedures are published or
                not.

               

            	 	
               

              $10,000,000

               

            
	
               

              18.

            	 	
               

              Actions
                in connection with product liability, including, without limitation,
                the
                testing of products developed by the Company and/or in connection
                with the
                distribution, sale, license or use of such products;

               

            	 	
               

              $10,000,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}]]